CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER (CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER).
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has bactericidal activity against a broad range of gram-positive and gram-negative bacteria.
| Metabolism | Ceftriaxone is not metabolized significantly; it is eliminated primarily unchanged in urine (33-67%) and bile (the remainder) via biliary secretion into feces. |
| Excretion | Renal (33-67% unchanged) and biliary (up to 40% as unchanged drug and microbiologically inactive metabolites); fecal elimination of unabsorbed drug is minimal. Dose adjustment required in combined renal and hepatic impairment. |
| Half-life | Terminal elimination half-life is approximately 5.8-8.7 hours in adults, prolonged to 12-24 hours in elderly, and up to 30-72 hours in neonates. No dose adjustment in renal impairment alone; adjust in severe hepatic impairment. |
| Protein binding | Approximately 95%, primarily to albumin; binding is saturable and concentration-dependent, decreasing at higher drug levels. |
| Volume of Distribution | 0.3-0.5 L/kg in adults, indicating distribution primarily into extracellular fluid; higher in neonates (0.5-3 L/kg) due to lower protein binding and body composition differences. |
| Bioavailability | Intravenous: 100%. Intramuscular: approximately 100% (rapid and complete absorption). |
| Onset of Action | Intravenous: immediate (minutes). Intramuscular: within 1-2 hours for peak plasma concentrations. |
| Duration of Action | Approximately 24 hours for most susceptible organisms due to prolonged half-life, allowing once-daily dosing. Bactericidal concentrations maintained for 12-24 hours. |
1-2 g intravenously or intramuscularly every 24 hours. Maximum dose: 4 g daily.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 10-50 mL/min: no adjustment needed. For GFR <10 mL/min: maximum dose 2 g every 24 hours. Hemodialysis: no supplemental dose required. |
| Liver impairment | No dose adjustment required for hepatic impairment. Caution in severe hepatic impairment with concurrent renal impairment. |
| Pediatric use | Neonates (0-28 days): 50 mg/kg intravenously or intramuscularly every 24 hours. Infants and children (1 month-12 years): 50-75 mg/kg IV or IM every 24 hours, maximum 2 g daily. For serious infections: up to 100 mg/kg daily, maximum 4 g. |
| Geriatric use | No specific dose adjustment except based on renal function. Standard adult dosing applies, with monitoring for renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER (CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER).
| Breastfeeding | Ceftriaxone is excreted in human milk in low concentrations (M/P ratio approximately 0.03-0.15). It is considered compatible with breastfeeding due to poor oral bioavailability in infants. Monitor infant for potential gastrointestinal disturbances or allergic reactions. |
| Teratogenic Risk | Ceftriaxone crosses the placenta. Animal studies have not shown fetal harm. No well-controlled human studies exist; however, cephalosporins are generally considered low risk. Use only if clearly needed. First trimester: limited data, no known teratogenicity. Second and third trimesters: no known fetal risk. |
■ FDA Black Box Warning
Ceftriaxone is contraindicated in neonates (≤28 days) if they require calcium-containing IV solutions due to risk of precipitation of ceftriaxone-calcium salt in lungs and kidneys.
| Serious Effects |
["Hypersensitivity to ceftriaxone or any cephalosporin","History of severe hypersensitivity (e.g., anaphylaxis) to penicillins or other beta-lactams","Neonates (≤28 days) with hyperbilirubinemia or those requiring calcium-containing IV solutions"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis","Clostridium difficile-associated diarrhea","Hemolytic anemia (immune-mediated)","Biliary pseudolithiasis and sludge","Acute renal failure (especially with high doses and concurrent nephrotoxic drugs)","Neuromuscular blockade exacerbation in myasthenia gravis","Superinfection with non-susceptible organisms"] |
| Food/Dietary | No known food interactions. Avoid alcohol consumption during treatment and for 48 hours after completion due to potential disulfiram-like reaction (though rare with ceftriaxone). |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal and hepatic function, CBC with differential, and signs of Clostridioides difficile diarrhea. Fetal monitoring: standard prenatal care. In prolonged therapy, monitor for superinfection and bleeding diathesis (due to vitamin K deficiency risk). |
| Fertility Effects | No known adverse effects on human fertility. Animal studies have not shown impaired fertility. |
| Clinical Pearls | CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER is a premixed, frozen antibiotic solution for IV administration. It must not be thawed by immersion in water or microwaved. Do not use if the container leaks or the solution is cloudy. Administer via IV infusion over 30 minutes. Calcium-containing solutions should not be administered within 48 hours of ceftriaxone due to risk of precipitation. Monitor renal function in patients with renal impairment. |
| Patient Advice | This medication is given through a vein (IV) and should not be mixed with calcium-containing IV solutions. · Inform your healthcare provider if you have a history of allergies to cephalosporins or penicillins. · Report any signs of allergic reaction such as rash, itching, difficulty breathing, or swelling. · Diarrhea, especially if watery or bloody, may occur; contact your doctor if this happens. · This medication may cause dizziness; avoid driving until you know how it affects you. |